Table of Contents

Mood stabilizers represent a critical class of psychiatric medications primarily used to manage mood disorders, with bipolar disorder being the most common indication. These medications help regulate extreme mood fluctuations, reducing the intensity and frequency of both manic and depressive episodes while promoting emotional stability. For mental health professionals, educators, and students in psychology and psychiatry, understanding the nuances of mood stabilizers is essential for effective patient care and treatment planning.

What Are Mood Stabilizers?

Mood stabilizers are a class of medications used in the management and treatment of bipolar disorder. These medications treat symptoms of bipolar disorder, a condition where individuals have both manic and depressive episodes. Unlike medications that simply elevate or suppress mood, mood stabilizers work to create a balanced emotional state, preventing the extreme highs of mania and the devastating lows of depression.

Mood stabilizers can help reduce many symptoms of mania, including rapid changes in emotions, sleep difficulties, racing thoughts and engaging in risky behaviors. They can also help prevent these symptoms from returning and the need for more intense treatment, like hospitalization. The primary goal of mood stabilizer therapy is to achieve and maintain euthymia—a normal, stable mood state—while minimizing the risk of relapse into either manic or depressive episodes.

Understanding Bipolar Disorder and the Need for Mood Stabilization

Bipolar disorder is comprised of two types: Bipolar I disorder is defined by at least one manic episode in a lifetime, while bipolar II disorder is defined by at least one past or present hypomanic episode with at least one past or present major depressive episode. The cyclical nature of bipolar disorder, with its alternating episodes of elevated and depressed mood, creates significant challenges for individuals living with the condition.

The impact of untreated bipolar disorder extends beyond mood symptoms. Individuals may experience disrupted relationships, impaired work performance, financial difficulties, and increased risk of substance abuse. Lithium is the only mood stabilizer that significantly reduces the risk of suicide, highlighting the life-saving potential of appropriate mood stabilizer treatment.

Types of Mood Stabilizers

There are three main types of mood stabilizers: lithium, anticonvulsants and antipsychotics. Each category has distinct mechanisms of action, benefits, and side effect profiles, making individualized treatment selection crucial for optimal outcomes.

Lithium: The Gold Standard Mood Stabilizer

Lithium is one of the most effective mood stabilisers for people with a mood disorder. Lithium is a naturally occurring element and has been approved by the U.S. Food and Drug Administration (FDA) as a mood stabilizer since 1970. Despite being discovered over 75 years ago, lithium remains a cornerstone of bipolar disorder treatment due to its proven efficacy across all phases of the illness.

Lithium and quetiapine top the lists for all three phases of the illness: mania, depression, and the maintenance phase. This comprehensive effectiveness makes lithium particularly valuable for long-term management. Lithium stands out for its preventative effects in bipolar disorder, and it is the only mood stabilizer that significantly reduces the risk of suicide, and it reduces mortality in other ways as well, including lowering the risk of cancer, heart disease, stroke, and viral illnesses.

How Lithium Works

The exact mechanism by which lithium stabilizes mood remains partially understood, though research has identified several key pathways. One of the best-known lithium mechanisms of action is the inhibition of glycogen synthase kinase-3 (GSK-3), an enzyme involved in a wide range of signal transduction pathways that influences the metabolism, proliferation, differentiation, development, and apoptosis of central nervous system cells.

Upon ingestion, lithium becomes widely distributed in the central nervous system and interacts with a number of neurotransmitters and receptors, decreasing norepinephrine release and increasing serotonin synthesis by neurons in the brain. Since GSK-3 has mainly a proapoptotic action, its inhibition by lithium may lead to neuroprotection, long-term plasticity, and mood stabilization.

Additional mechanisms include effects on the GABA neurotransmitter system. Lithium has been shown to increase the level of GABA in plasma and cerebral spinal fluid. This is particularly important because GABA is an inhibitory neurotransmitter that helps regulate dopamine and glutamate neurotransmission, both of which are implicated in mood regulation.

Lithium Monitoring and Therapeutic Levels

Lithium has a very narrow therapeutic window for maintenance therapy—too little lithium risks undertreatment of the mood disorder and increases the risk of relapse, while too much lithium increases the risk of both acute and chronic toxicity. This necessitates regular blood level monitoring to ensure therapeutic efficacy while avoiding toxicity.

For the maintenance phase of treatment, recent guidelines recommend that patients maintain a serum concentration of 0.6–0.8 mmol/L to maximise therapeutic benefit, while for acute treatment in mania, serum concentrations should be increased to 0.6–1.0 mmol/L as tolerated, and in depression, concentrations can be in the range of 0.4–0.8 mmol/L. Lithium concentrations should always be measured 12 hours after the last dose.

Drug Interactions with Lithium

Lithium clearance is easily influenced by drugs that alter renal function such as ACE inhibitors, angiotensin receptor antagonists, diuretics, and non-steroidal anti-inflammatory drugs. Patients on lithium therapy should be advised to avoid NSAIDs, as regular use is more problematic than episodic use. When NSAIDs are necessary, closer monitoring of lithium levels and dose adjustments may be required.

Anticonvulsants as Mood Stabilizers

Anticonvulsant medications, originally developed to treat epilepsy, have proven effective in managing bipolar disorder. The first-line treatments are mood-stabilizing agents, such as lithium and anticonvulsants (valproate, carbamazepine, and lamotrigine). These medications offer alternatives for patients who cannot tolerate lithium or who require additional mood stabilization.

Valproate (Divalproex)

Valproate, also known as divalproex or valproic acid, is widely used for acute mania and maintenance treatment of bipolar disorder. A suggested common mechanism for mood-stabilizing abilities is inhibition of the inositol uptake process, resulting in inositol depletion, where the myo-inositol monophosphate transporter and its respective mRNA become downregulated by major mood-stabilizing agents.

Valproate is particularly useful for patients with mixed episodes or rapid cycling bipolar disorder. It can be used as monotherapy or in combination with other mood stabilizers or antipsychotics for enhanced efficacy.

Lamotrigine

Lamotrigine belongs to the group of antiepileptic drugs and mood stabilizers, and its action is based on the selective blocking of voltage-deficient sodium channels. Lurasidone and lamotrigine are either untested (lurasidone) or ineffective (lamotrigine) in mania, but they are essential tools for bipolar depression.

Lamotrigine has a number needed to treat (NNT) of 12, and is the better tolerated option, with few of the adverse effects that matter most to patients: weight gain, fatigue, sexual dysfunction, and long-term medical risks. Lamotrigine is better at preventing depression than it is at treating it. This makes lamotrigine particularly valuable for maintenance therapy in patients prone to depressive episodes.

Lamotrigine helps delay episodes in bipolar 1 and prevent depression in bipolar 2 disorder, though it may be less effective at treating acute depression or mania. The medication requires slow titration to minimize the risk of serious rash, including Stevens-Johnson syndrome, which is a rare but potentially life-threatening side effect.

Carbamazepine

Carbamazepine is another anticonvulsant used in bipolar disorder treatment, particularly for patients who have not responded adequately to lithium or valproate. Like other anticonvulsants, it works through multiple mechanisms, including sodium channel blockade and effects on neurotransmitter systems. Carbamazepine requires regular monitoring of blood levels and liver function due to potential side effects and drug interactions.

Atypical Antipsychotics

Atypical antipsychotics, also called second-generation antipsychotics, have become increasingly important in bipolar disorder treatment. The review focuses on the mechanism and clinical aspects of second-generation antipsychotic medications; aripiprazole, classified as a third-generation antipsychotic medication; lamotrigine, as a representative of antiepileptic drugs; and lurasidone, a novel second-generation antipsychotic medication.

Quetiapine

Medications approved to treat bipolar depression include cariprazine (Vraylar), lurasidone (Latuda), olanzapine-fluoxetine combo (Symbyax), and quetiapine (Seroquel), with lurasidone offering a good balance of efficacy and tolerability. Quetiapine is effective across all phases of bipolar disorder, making it a versatile option for both acute treatment and maintenance therapy.

Lurasidone

Lurasidone has emerged as an important treatment option specifically for bipolar depression. Lurasidone is the more effective of the two, with a number needed to treat (NNT) of 5 compared to lamotrigine's 12. Lurasidone's main problems—nausea, akathisia, cost, and lack of evidence in mania—are less likely to occur with quetiapine.

Cariprazine

One of the newest and most highly effective normothymic drugs is cariprazine. This medication has demonstrated efficacy in treating both manic and depressive episodes in bipolar I disorder, offering another valuable option in the therapeutic arsenal.

Olanzapine

Olanzapine is a mood-stabilizing drug that has antimanic effects and is registered for the treatment of schizophrenia and moderate and severe manic episodes, and for the prevention of relapses of bipolar disorder. One study showed that olanzapine reduced the relapse rate of bipolar disorder, compared with placebo—for those taking olanzapine, the average time without disease activity until relapse was 174 days, and for placebo, it was 22 days, with the incidence of relapse significantly lower in the olanzapine group (46.7%) vs placebo (80.1%).

Aripiprazole

Aripiprazole is classified as a third-generation antipsychotic with a unique mechanism of action as a partial dopamine agonist. This property may contribute to a more favorable side effect profile compared to some other antipsychotics, particularly regarding metabolic effects and extrapyramidal symptoms.

How Mood Stabilizers Work: Mechanisms of Action

Mood stabilizers work by affecting certain receptors in the brain that regulate the release and maintenance of neurotransmitters, and it's thought that by modulating this activity, mood stabilizers can improve symptoms of bipolar disorder, as well as other psychiatric conditions. The specific mechanisms vary considerably among different classes of mood stabilizers.

Neurotransmitter Modulation

Mood stabilizers influence multiple neurotransmitter systems implicated in mood regulation, including serotonin, dopamine, glutamate, and GABA. By modulating these chemical messengers, mood stabilizers help restore balance to neural circuits involved in emotional regulation, impulse control, and cognitive function.

The complexity of these mechanisms reflects the multifaceted nature of bipolar disorder itself. Rather than targeting a single neurotransmitter system, effective mood stabilizers typically influence multiple pathways simultaneously, contributing to their broad therapeutic effects.

Neuroprotective Effects

Lithium affects the intrinsic apoptotic pathway regulated primarily by the Bax protein and downregulated by the anti-apoptotic protein Bcl-2—long-term lithium treatment decreases p53 and Bax protein production and significantly augments transcription of the Bcl-2 gene, resulting in a neuroprotective effect. These neuroprotective properties may contribute to the long-term benefits of mood stabilizer treatment beyond acute symptom control.

Cellular Resilience and Stress Response

Emerging research suggests that mood stabilizers enhance cellular resilience and improve stress response mechanisms in the brain. This may help explain why these medications not only treat acute episodes but also prevent future mood episodes when used as maintenance therapy.

Clinical Benefits of Mood Stabilizers

The therapeutic benefits of mood stabilizers extend across multiple domains of functioning and quality of life for individuals with bipolar disorder.

Reduction in Manic Episodes

Mood stabilizers effectively reduce the frequency, duration, and severity of manic episodes. During acute mania, these medications help control symptoms such as elevated mood, increased energy, decreased need for sleep, racing thoughts, impulsivity, and risky behavior. The antimanic effects typically become apparent within one to two weeks of initiating treatment at therapeutic doses.

Prevention of Depressive Episodes

While some mood stabilizers are more effective than others for bipolar depression, the class as a whole helps reduce depressive episodes. Medications like lamotrigine and lurasidone have particular efficacy in treating and preventing bipolar depression, addressing a critical need given that depressive episodes often cause more functional impairment than manic episodes.

Maintenance of Mood Stability

Maintenance of the therapeutic concentration (and adherence) is the strongest predictor of long-term stability. Consistent use of mood stabilizers during euthymic periods significantly reduces the risk of relapse into either mania or depression, allowing individuals to maintain stable functioning over extended periods.

Suicide Prevention

Lithium has the strongest evidence base for suicide prevention in bipolar disorder and related mood disorders, demonstrating consistent reductions in suicide risk across randomized controlled trials, long-term observational cohorts, and meta-analyses. A landmark meta-analysis found that lithium significantly reduced suicides and deliberate self-harm compared to placebo or other pharmacological agents, with this effect evident not only in bipolar disorder but also in recurrent unipolar depression.

Subsequent systematic reviews showed lithium reduced suicide risk by nearly 60% compared with alternatives such as carbamazepine or valproate. This unique anti-suicidal property makes lithium particularly valuable for patients at elevated suicide risk.

Improved Quality of Life

By reducing mood episode frequency and severity, mood stabilizers enable individuals with bipolar disorder to maintain employment, sustain relationships, pursue educational goals, and engage in meaningful activities. The overall improvement in functioning and quality of life represents one of the most important outcomes of effective mood stabilizer treatment.

Potential Side Effects and Adverse Reactions

Like all medications, mood stabilizers can produce side effects that vary in frequency and severity depending on the specific medication, dosage, and individual patient factors.

Common Side Effects Across Mood Stabilizers

Weight gain represents one of the most common and concerning side effects of many mood stabilizers, particularly certain atypical antipsychotics like olanzapine and quetiapine. This can lead to metabolic complications including diabetes and cardiovascular disease if not properly monitored and managed.

Drowsiness and sedation are frequently reported, especially during initial treatment or dose adjustments. While this can be problematic for daytime functioning, it may be beneficial for patients experiencing insomnia during manic episodes.

Gastrointestinal symptoms including nausea, vomiting, and diarrhea can occur with various mood stabilizers. These effects are often dose-related and may improve over time as the body adjusts to the medication.

Tremor, particularly fine hand tremor, is commonly associated with lithium and valproate. While usually mild, tremor can interfere with fine motor tasks and may require dose adjustment or addition of beta-blockers for management.

Lithium-Specific Side Effects

High levels of lithium in blood can be dangerous. Lithium toxicity can manifest as coarse tremor, confusion, ataxia, seizures, and in severe cases, coma or death. This underscores the critical importance of regular blood level monitoring.

Thyroid dysfunction occurs in a significant proportion of patients on long-term lithium therapy, with hypothyroidism being the most common manifestation. Regular thyroid function testing is essential, and thyroid hormone replacement may be necessary.

Kidney effects, including impaired concentrating ability leading to polyuria (excessive urination) and polydipsia (excessive thirst), can develop with chronic lithium use. More serious renal complications are rare but require monitoring of kidney function.

Anticonvulsant-Specific Side Effects

Valproate can cause hepatotoxicity, particularly in young children and patients with certain genetic conditions. Regular liver function monitoring is required, especially during the first six months of treatment.

Lamotrigine carries a risk of serious rash, including Stevens-Johnson syndrome and toxic epidermal necrolysis. The risk is minimized through slow dose titration and careful monitoring, particularly during the first few months of treatment.

Carbamazepine can cause blood dyscrasias, including potentially serious conditions like aplastic anemia and agranulocytosis, though these are rare. Regular blood count monitoring is recommended.

Antipsychotic-Specific Side Effects

Metabolic syndrome, characterized by weight gain, elevated blood glucose, dyslipidemia, and hypertension, is a significant concern with many atypical antipsychotics. Regular metabolic monitoring including weight, blood glucose, and lipid panels is essential.

Extrapyramidal symptoms (EPS), including akathisia (restlessness), dystonia (muscle spasms), and parkinsonism, can occur with antipsychotics, though atypical agents generally have lower risk than older typical antipsychotics.

Hyperprolactinemia, leading to galactorrhea, amenorrhea, and sexual dysfunction, can occur with certain antipsychotics, particularly risperidone and paliperidone.

Clinical Considerations for Mood Stabilizer Use

The manic and depressive characteristics of bipolar disorder require particular mood stabilizers that can cater to the patient's individual needs, with different agents having strengths and weaknesses owing to their indications, contraindications, and their protocol for follow-up, and clinicians are encouraged to choose a mood stabilizer keeping these different factors in mind.

Patient History and Diagnosis

The specific type of bipolar disorder (I vs. II), predominant polarity (more manic vs. more depressive episodes), presence of rapid cycling, mixed features, and psychotic symptoms all influence medication selection. A thorough psychiatric history, including response to previous treatments, helps guide optimal medication choice.

Comorbid medical conditions significantly impact mood stabilizer selection. For example, patients with kidney disease may not be suitable candidates for lithium, while those with liver disease require careful consideration before using valproate.

Drug Interactions

The fact that the common medications included in this class have significant drug-drug interactions merits close scrutiny, and the patient's clinician should always confer with a pharmacist to decide which agent would perform best, given the patient's current needs. Comprehensive medication review is essential before initiating mood stabilizer therapy.

Interactions can affect both the mood stabilizer and concomitant medications. For instance, carbamazepine is a potent enzyme inducer that can reduce levels of many other medications, including oral contraceptives, requiring dose adjustments or alternative contraceptive methods.

Monitoring Requirements

Aside from the initial council necessary before initiating a mood stabilizer regimen, the patient will need to follow up regularly for monitoring, and nursing can play a significant role in both of these activities. Monitoring protocols vary by medication but generally include:

  • Blood level monitoring for lithium, valproate, and carbamazepine
  • Kidney function tests, particularly for lithium
  • Liver function tests, especially for valproate and carbamazepine
  • Thyroid function monitoring for lithium
  • Complete blood counts for carbamazepine and valproate
  • Metabolic parameters (weight, glucose, lipids) for atypical antipsychotics
  • Pregnancy testing for women of childbearing potential, as many mood stabilizers have teratogenic potential

Patient Preferences and Lifestyle Factors

Shared decision-making that incorporates patient preferences improves treatment adherence and outcomes. Factors to discuss include dosing frequency, side effect tolerability, monitoring burden, and impact on daily activities.

For women of childbearing potential, teratogenic risks must be carefully discussed. Valproate carries particularly high risk of neural tube defects and developmental delays and is generally avoided in this population. Lithium also carries teratogenic risk, particularly for cardiac malformations, requiring careful risk-benefit analysis.

Combination Therapy

In some patients, stabilising their mood is not always possible with lithium alone, and a trial with other mood stabilisers, such as adjunctive sodium valproate or an atypical antipsychotic, is often necessary. Combination therapy may provide superior efficacy for patients with severe or treatment-resistant bipolar disorder.

Mood stabilizers may be used alone or can be combined with antipsychotics and other medicines. Common combinations include lithium plus an atypical antipsychotic, or an anticonvulsant plus an antipsychotic. The choice of combination depends on the specific symptom profile and treatment history.

Emerging Treatments and Future Directions

According to National Institutes of Health recent research, 75 years after lithium's discovery, ongoing Phase II and III clinical trials (as of April 2024) focus on repurposing existing drugs and developing innovative therapies targeting mood-related neuroinflammation, dopamine stabilization, and serotonin receptor activities.

Novel Antipsychotics

The potential of new mood stabilizer candidates lumateperone and brexpiprazole is also presented. These newer agents may offer improved efficacy or tolerability compared to existing options.

In April 2024, Vanda Pharmaceuticals announced U.S. FDA approval for Fanapt (iloperidone) for treating manic episodes in bipolar I disorder, expanding the available therapeutic options, reflecting the growing focus on innovative treatments to address the rising prevalence of bipolar disorder.

Rapid-Acting Treatments

In January 2025, Johnson & Johnson received U.S. FDA approval for SPRAVATO (esketamine) as the first and only monotherapy for treatment-resistant depression (TRD) in adults, demonstrating rapid symptom relief within 24 hours and significantly higher remission rates (22.5% vs. 7.6% on placebo) by week 4. While primarily approved for treatment-resistant depression, esketamine's potential application in bipolar depression is being explored.

Long-Acting Injectable Formulations

Long-acting injectable formulations—such as those being developed for mood stabilization—are poised to address non-compliance and relapse rates by maintaining consistent plasma levels over weeks, offering clinical advantages that align with payor and provider demands for outcomes-based mental health management.

Immunomodulatory Approaches

According to the assumptions of psychoneuroimmunology, impaired regulation of immune system activity and chronic inflammation may play an essential role in the pathogenesis of bipolar disorder, and numerous studies indicate that the treatment of depressive disorders, including bipolar disorder, can be effective by modifying the immune response, therefore further research is needed to understand the connection between immune system modulation and the therapeutic action of lithium.

Special Populations

Pregnancy and Lactation

Managing bipolar disorder during pregnancy requires careful balancing of maternal mental health needs against potential fetal risks. All mood stabilizers carry some degree of teratogenic risk, with valproate posing the highest risk and generally being contraindicated in pregnancy.

Lithium use during pregnancy requires specialized monitoring, including fetal echocardiography to screen for cardiac malformations and adjustment of doses throughout pregnancy as renal clearance changes. Many women require dose increases during pregnancy and rapid dose reduction after delivery to avoid toxicity.

Most mood stabilizers are excreted in breast milk, requiring individualized risk-benefit assessment for breastfeeding mothers. Some women may choose to discontinue breastfeeding to continue necessary mood stabilizer therapy, while others may use medications with lower breast milk transfer.

Elderly Patients

Older adults with bipolar disorder require special consideration due to age-related changes in drug metabolism, increased sensitivity to side effects, and higher rates of medical comorbidities. Lower doses are often required, and more frequent monitoring may be necessary.

Lithium clearance decreases with age, necessitating lower doses to achieve therapeutic levels. Elderly patients are also more susceptible to lithium toxicity and cognitive side effects. Careful monitoring of kidney function and drug interactions is essential.

Adolescents and Young Adults

In February 2025, UCLA Health announced a 16-week pilot study to assess whether a ketogenic diet, alongside mood-stabilizing medications, can help stabilize mood symptoms in youth aged 12–21 with bipolar disorder, marking the first study of its kind in adolescents. This reflects growing interest in comprehensive treatment approaches for younger patients.

Adolescents with bipolar disorder present unique challenges, including diagnostic uncertainty, developmental considerations, and concerns about long-term medication effects. Mood stabilizers used in this population require careful monitoring for effects on growth, development, and metabolic parameters.

Adherence and Treatment Engagement

Medication non-adherence represents a major challenge in bipolar disorder treatment, with rates of non-adherence ranging from 20-60% in various studies. Factors contributing to non-adherence include side effects, lack of insight during manic episodes, feeling well and not perceiving need for medication, complexity of regimens, and stigma associated with mental illness.

Strategies to Improve Adherence

Psychoeducation about bipolar disorder and the role of mood stabilizers in preventing relapse is fundamental. Patients who understand their illness and treatment rationale demonstrate better adherence.

Simplifying medication regimens when possible, such as using once-daily formulations or reducing the total number of medications, can improve adherence. Extended-release formulations may offer advantages in terms of both adherence and tolerability.

Regular follow-up and therapeutic alliance with healthcare providers supports ongoing treatment engagement. Involving family members or support persons, when appropriate, can provide additional monitoring and encouragement.

Addressing side effects proactively through dose adjustments, medication changes, or addition of medications to manage side effects demonstrates responsiveness to patient concerns and may prevent treatment discontinuation.

The Role of Psychotherapy and Psychosocial Interventions

While mood stabilizers form the foundation of bipolar disorder treatment, optimal outcomes typically require integration of psychotherapy and psychosocial interventions. Evidence-based psychotherapies for bipolar disorder include cognitive-behavioral therapy (CBT), interpersonal and social rhythm therapy (IPSRT), family-focused therapy, and psychoeducation.

These interventions help patients recognize early warning signs of mood episodes, develop coping strategies, improve medication adherence, address interpersonal problems, and regulate sleep-wake cycles and daily routines. The combination of pharmacotherapy and psychotherapy produces superior outcomes compared to medication alone.

Conclusion

Mood stabilizers represent an indispensable component of modern psychiatric treatment, particularly for bipolar disorder. Mood stabilizers represent a class of medications that can be expertly used in treatment regimens for bipolar mania and bipolar depression when used and managed correctly, with evaluation of specific mood-stabilizing agents tailored to each patient's diagnosis and needs through a team-based approach to pharmacologic management.

From lithium, the gold standard with over 70 years of clinical use, to newer atypical antipsychotics and anticonvulsants, the mood stabilizer class offers diverse options to address the complex and heterogeneous presentations of bipolar disorder. Each medication brings unique benefits and challenges, requiring individualized treatment selection based on patient characteristics, symptom profile, comorbidities, and preferences.

Many of the new drugs have strong potential to be beneficial and safe in cases of many comorbidities, as they do not cause many adverse effects and do not require high doses of use, with results underscoring the importance of ongoing and future research to better understand the action and efficacy of these mood stabilizers.

For mental health professionals, educators, and students, comprehensive understanding of mood stabilizers—including their mechanisms of action, clinical applications, monitoring requirements, and potential adverse effects—is essential for providing evidence-based, patient-centered care. As research continues to elucidate the neurobiology of bipolar disorder and develop novel therapeutic approaches, the future holds promise for even more effective and tolerable treatments.

The ultimate goal of mood stabilizer therapy extends beyond symptom control to helping individuals with bipolar disorder achieve stable mood, optimal functioning, meaningful relationships, and fulfilling lives. Through careful medication selection, diligent monitoring, collaborative treatment planning, and integration with psychosocial interventions, mood stabilizers can transform the trajectory of bipolar disorder from a devastating chronic illness to a manageable condition compatible with recovery and wellness.

For more information about bipolar disorder and mental health treatment, visit the National Institute of Mental Health or the National Alliance on Mental Illness. Healthcare professionals seeking clinical guidelines can consult the American Psychiatric Association Practice Guidelines or the Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines.